- Conditions
- Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML)
- Interventions
- birinapant, Azacitidine, Placebo
- Drug
- Lead sponsor
- TetraLogic Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 118 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 46
- States / cities
- Glendale, Arizona • Scottsdale, Arizona • Tucson, Arizona + 39 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–9
of 9
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Myelodysplastic Syndrome
- Interventions
- Birinapant, 5-Azacitidine
- Drug
- Lead sponsor
- TetraLogic Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 7
- States / cities
- Glendale, Arizona • Scottsdale, Arizona • Fresno, California + 4 more
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- Smac mimetic TL32711, gemcitabine hydrochloride, laboratory biomarker analysis, pharmacological study, biopsy
- Drug · Other · Procedure
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2012
- U.S. locations
- 2
- States / cities
- Buffalo, New York • Philadelphia, Pennsylvania
- Conditions
- Relapsed Epithelial Ovarian Cancer, Relapsed Primary Peritoneal Cancer, Relapsed Fallopian Tube Cancer
- Interventions
- Birinapant, Conatumumab
- Drug
- Lead sponsor
- TetraLogic Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 9
- States / cities
- Fresno, California • San Luis Obispo, California • Fairway, Kansas + 5 more
- Conditions
- Cancer
- Interventions
- Birinapant (TL32711)
- Drug
- Lead sponsor
- TetraLogic Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 3
- States / cities
- Buffalo, New York • Philadelphia, Pennsylvania
- Conditions
- Lymphoma, T-Cell, Cutaneous
- Interventions
- placebo for SHAPE (SHP-141), SHAPE (SHP-141) 0.1% BID, SHAPE (SHP-141) 0.5% BID, SHAPE (SHP-141) 1.0% BID
- Drug
- Lead sponsor
- TetraLogic Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 6
- States / cities
- Stanford, California • Chicago, Illinois • Cleveland, Ohio + 2 more
- Conditions
- Cancer
- Interventions
- Birinapant
- Drug
- Lead sponsor
- TetraLogic Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 176 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 7
- States / cities
- Fort Lauderdale, Florida • Detroit, Michigan • Buffalo, New York + 3 more
- Conditions
- High Grade Fallopian Tube Serous Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Interventions
- Birinapant, Carboplatin, Laboratory Biomarker Analysis, Pharmacological Study
- Drug · Other
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Cutaneous T-Cell Lymphoma (CTCL)
- Interventions
- SHAPE
- Drug
- Lead sponsor
- TetraLogic Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 5
- States / cities
- Stanford, California • Chicago, Illinois • Boston, Massachusetts + 2 more